Merck has entered into a definitive agreement to acquire Tilos Therapeutics, a privately held biopharmaceutical company developing therapeutics targeting the latent TGFβ complex for the treatment of cancer, fibrosis and autoimmune diseases for $773 million.   “At Merck we continue to enhance our robust pipeline through active execution of our business development strategy,” said Dean Li, senior vice president, discovery and translational medicine, Merck Research Laboratories. “Tilos has de...